-
Mashup Score: 1Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma - 1 day(s) ago
Blood Cancer Journal – Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Clinician attitudes and practices toward measurable residual disease in multiple myeloma - 1 day(s) ago
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0#mmMRD - Healthcare Social Media Analytics and Transcripts - 1 day(s) ago
What is #mmMRD? measurable residual disease, minimal residual disease, Multiple Myeloma. Healthcare Social Media Hashtag. Real-time Analytics.
Source: www.symplur.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf
-
-
Mashup Score: 7CTG Labs - NCBI - 1 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4CTG Labs - NCBI - 1 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMxByG #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd https://t.co/GQN5ltIS4s
-
-
Mashup Score: 3Oncology precision medicine for hepatobiliary and pancreatic cancer: Insights and updates from a large community health system - 1 day(s) ago
By Geoffrey Bellini, Nicholas Sich, Jennifer Godden, et al., Published on 05/20/20
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet-
Oncology #PrecisionMedicine for hepatobiliary & pancreatic cancer: Insights & updates from a large community health system [5/20/20] Bellini Sich Godden @JimW9200 @WesleyPapenfuss Chevinsky @antonyruggeri @mtmdphd @Aurora_Health Scientific Day #44 https://t.co/66KdQ3TXf3 #hpbcsm https://t.co/UrUybQYmKb
-
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 1 day(s) ago
Geoffrey Bellini Aurora St. Luke’s Medical Center, Milwaukee, WI Geoffrey Bellini, Nicholas Sich, Jennifer Jo Godden, James L. Weese, Wesley Allan Papenfuss, Aaron Chevinsky, Antony Ruggeri, Michael A. Thompson Aurora St. Luke’s Medical Center, Milwaukee, WI, Advocate Aurora Health, Milwaukee, WI, Aurora Health Care, Milwaukee, WI, Aurora Advanced Healthcare, Wauwatosa, WI Background: Hepatobiliary cancers – hepatocellular carcinoma (HCC), intra or extrahepatic cholangiocarcinoma (I/EC), and gallbladder
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Oncology precision medicine for hepatobiliary and pancreatic cancer: An institutional review. - 1 day(s) ago
e14626 Background: Hepatobiliary cancers – hepatocellular carcinoma (HCC), intra or extrahepatic cholangiocarcinoma (I/EC), and gallbladder carcinoma (GB) – and pancreatic adenocarcinoma (PC) remain a leading cause of death with little improvement in long-term outcome. Recent studies have suggested that these cancers harbor actionable mutations to varying degrees. The aim of our study was to examine the number of patients (Pts) with these primary tumors who underwent molecular testing in a large vertically integrated health system. Subsequently, we analyzed the percentage of that population who may be candidates for oncology precision medicine (OPM) directed therapy. Methods: We identified Pts with HCC, IC, EC, GB in an IRB reviewed OPM database of our system over a one year period. Pts who underwent molecular panel testing were selected out, and their molecular alterations were identified and stratified by cancer type. Results: 304 total Pts were identified. 61 (20%) underwent molecul
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies - 1 day(s) ago
Background: The predictive and prognostic role of BRAF alterations has been evaluated in colorectal cancer (CRC); however, BRAF alterations have not been fully characterized in non-CRC gastrointestinal (GI) malignancies. In the present study, we report the frequency and spectrum of BRAF alterations among patients with non-CRC GI malignancies. Methods: Patients with CRC and non-CRC GI malignancies who underwent somatic tumor profiling via a tissue-based or liquid-based assay were included in this study. Gain-of-function BRAF alterations were defined as pathogenic/likely pathogenic somatic short variants (SVs), copy number amplifications ≥8, or fusions (RNA or DNA). Results: Among 51,560 patients with somatic profiling, 40% had CRC and 60% had non-CRC GI malignancies. BRAF GOF alterations were seen more frequently in CRC (8.9%) compared to non-CRC GI malignancies (2.2%) (p < 0.001). Non-CRC GI malignancies with the highest prevalence of BRAF GOF alterations were bile duct cancers (4.1%)
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma [Jul 11, 2022] @bdermanmd @ajjakubowiak @mtmdphd @BloodCancerJnl https://t.co/oioEadhwgW #mmMRD #mmsm #openaccess https://t.co/6nAQYYyW3B